An observational study in Pulmonary Fibrosis, COPD and Asthma, sponsored by Wissenschaftliches Institut Bethanien e.V. Completed at 1 site in Germany. Per ClinicalTrials.gov, last updated 2024-05-07.
Sponsored by Wissenschaftliches Institut Bethanien e.V · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Pulmonary Fibrosis with a site in Germany — 4 open to participants now, 8 under way, 3 of them phase 3. Pulmonary Fibrosis · Germany.
Among the 25 studies in Pulmonary Fibrosis with a site in Germany, this one is one of 3 that started in 2021, is one of 4 observational ones, and was the 21st registered.
342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.
Browse Pulmonary Fibrosis studies →4 of the 25 studies in Pulmonary Fibrosis with a site in Germany are open now. Recruiting first, the newest first:
Contineum Therapeutics · Sites in Germany, Argentina, Australia and 16 more countries
Ages 40+
University of Ulm · Sites in Germany
Ages 18–90 · Healthy volunteers
Matthias Griese · Sites in Germany, Turkey, United Kingdom
Bristol-Myers Squibb · Sites in Germany, United States, Argentina and 24 more countries
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is below the median of 150 across 118 observational studies indexed under Pulmonary Fibrosis.
Median enrollment 320 across the 21 interventional studies, 345 across the 4 observational. Of the 16 that completed or were terminated, 10 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 25 have an industry lead sponsor. The 10 most frequent:
Wissenschaftliches Institut Bethanien e.V is the lead sponsor of 25 studies on the registry; 2 are open to participants now.
Wissenschaftliches Institut Bethanien e.V has 1 study filed under Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Pulmonary Fibrosis with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06329401Avalyn Pharma Inc.A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies in Pulmonary Fibrosis with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Comparison of the new multiple-breath washout method (ndd Medizintechnik Zürich, Trueflow™/Truecheck™) with established methods of lung function diagnostics in patients with idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, asthma and cardiopulmonary healthy individuals.
This diagnostic, prospective, clinical study aims to investigate whether the lung function data measured with the EasyOnePro®LAB device correlates with the lung function data from established measurement methods used in routine clinical practice. It is to be investigated whether the EasyOnePro®LAB measurement leads to equivalent results even with a shorter measurement duration due to an improved evaluation. This is relevant for a broader clinical application in the future.
It will also be tested whether the fact that the EasyOnePro®LAB measurement can be carried out largely independently of the employee also leads to better reproducibility of the results. To this end, the intra-individual deviations in repeated measurements will be compared between the methods.
Patients admitted to the study center with one of the above-mentioned diseases
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in whom there is no evidence of cardiopulmonary dysfunction in the course of diagnostics
Diagnostic Test: Multiple-Breath-Washout
idiopathic pulmonary fibrosis (IPF), confirmed according to the guidelines
Diagnostic Test: Multiple-Breath-Washout
Chronic obstructive pulmonary disease (COPD) with/without emphysema
Diagnostic Test: Multiple-Breath-Washout
Diagnostic Test: Multiple-Breath-Washout
One additional diagnostic test is performed using the Multiple-Breath-Washout technology
Lung Clearance Index
comparison of the lung clearance index of the different patient groups
Time frame: immediately ofter the procedure
Ran from Jun 2021 to primary completion in Mar 2024, 32 months.
Of 60 observational studies under Pulmonary Fibrosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 111. This study's 32 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wissenschaftliches Institut Bethanien e.V